The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review

PloS One
Jaana T JoensuuMarja Blom

Abstract

Economic evaluations provide information to aid the optimal utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. This systematic review aims to identify existing studies examining the cost-effectiveness of biologics for RA, assess their quality and report their results systematically. A literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web of Science was performed in March 2013. The cost-utility analyses (CUAs) of one or more available biological drugs for the treatment of RA in adults were included. Two independent investigators systematically collected information and assessed the quality of the studies. To enable the comparison of the results, all costs were converted to 2013 euro. Of the 4890 references found in the literature search, 41 CUAs were included in the current systematic review. While considering only direct costs, the incremental cost-effectiveness ratio (ICER) of the tumor necrosis factor inhibitors (TNFi) ranged from 39,000 to 1,273,000 €/quality adjusted life year (QALY) gained in comparison to conventional disease-modifying antirheumatic drugs (...Continue Reading

References

Oct 29, 2002·The American Journal of Medicine·John B WongArthur Kavanaugh
Sep 14, 2004·Health Technology Assessment : HTA·Z PhilipsJ Glanville
May 12, 2007·Journal of Clinical Epidemiology·C A MarraA H Anis
Dec 25, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J LundkvistG Kobelt
Apr 3, 2008·Arthritis and Rheumatism·Allan J WailooFred Wolfe
Apr 18, 2008·Journal of Human Hypertension·M I Perez, V M Musini
Nov 18, 2008·The Journal of Rheumatology·Andrew DaviesMichael H Weisman
Feb 28, 2009·Arthritis and Rheumatism·Wilbert B van den HoutFerdinand C Breedveld
Apr 1, 2009·International Journal of Technology Assessment in Health Care·Peter LindgrenGisela Kobelt
Jun 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Chiun-Fang ChiouCarolina M Reyes
Dec 8, 2009·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Sonja MerkesdalAndrea Rubbert-Roth
Jan 12, 2010·International Journal of Technology Assessment in Health Care·Ingrid LekanderRonald F van Vollenhoven
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David C HoaglinAnnabel Barrett
Jul 9, 2011·International Journal of Technology Assessment in Health Care·Gisela KobeltPierre Geborek
Feb 9, 2012·Journal of Medical Economics·Alexander DiamantopoulosWalter Ricciardi
Sep 20, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ingrid LekanderGisela Kobelt
Dec 12, 2012·Best Practice & Research. Clinical Rheumatology·Nicole W TsaoCarlo A Marra

❮ Previous
Next ❯

Citations

Sep 24, 2015·Expert Review of Clinical Immunology·László GulácsiMárta Péntek
Jul 13, 2016·Current Rheumatology Reports·Filipe C AraújoJoão Eurico Fonseca
Apr 11, 2017·Current Medicinal Chemistry·Laszlo GulacsiPeter L Lakatos
Mar 31, 2016·Annals of the Rheumatic Diseases·Rudra Prosad GoswamiAlakendu Ghosh
Jan 19, 2019·Advances in Rheumatology·Licia Maria Henrique da MotaRina Dalva Neubarth Giorgi
Jan 24, 2020·Journal of Medical Economics·Matthew SussmanJoseph Menzin
Aug 6, 2020·Frontiers in Bioengineering and Biotechnology·Pingping WangDi Xu
Aug 11, 2018·Applied Health Economics and Health Policy·Jamison Pike, Scott D Grosse
Aug 11, 2020·Pain Research & Management : the Journal of the Canadian Pain Society = Journal De La Société Canadienne Pour Le Traitement De La Douleur·Akira HashimotoMasaaki Mawatari
Aug 4, 2018·Frontiers in Pharmacology·Vladimira V BoyadzievaGuenka I Petrova
Jan 31, 2017·Rheumatology International·Yoon-Kyoung SungUNKNOWN BIOPSY and KORONA investigators
Dec 31, 2020·Journal of Managed Care & Specialty Pharmacy·Aliza R Karpes MatusevichMaria A Lopez-Olivo
Feb 18, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Elisabetta ChessaAlberto Cauli

❮ Previous
Next ❯

Software Mentioned

Excel
CEA
ACP
Refworks

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.